Hubei Yuancheng Saichuang Technology Co.,Ltd.


  Reliable Raw Steroid Powder Supplier In China-Professional,Efficient, Creditable   

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
News
Home ProductsOral Anabolic Steroids

81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills

I'm Online Chat Now
China Hubei Yuancheng Saichuang Technology Co., Ltd. certification
China Hubei Yuancheng Saichuang Technology Co., Ltd. certification
I did receive the parcel and brewed up the gear.I am very impressed and pleased with your products.You have me as a customer for life !

—— Andrew

Yes,I have received everything.I really appreciate you!!This has proven to be an excellent business relationship.I am very happy !!

—— Jameson

Well everyone is loving your products so I will be doing business strictly with you going forward!!

—— Nona

81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills

81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills
81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills 81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills 81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills 81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills 81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills

Large Image :  81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills Get Best Price

Product Details:
Place of Origin: China
Brand Name: BNP
Certification: SGS
Model Number: cas 81409-90-7
Payment & Shipping Terms:
Minimum Order Quantity: 1bottle, 25 pills per bottle
Price: Negotiated
Packaging Details: glass bottle
Delivery Time: within 24 hours after the payment
Payment Terms: Bank Transfer, T/T, Western Union, MoneyGram, Bitcoin
Supply Ability: 500bottles/month
Detailed Product Description
Name: Dostinex Specification: Oral Pills
Shipping Method: Fedex, DHL, UPS, USPS, EMS, ETK... Other Name: Cabergoline
Whatsapp: +8613119583676 Payment: Money Gram, Western Union, Bank Transfer, Bitcoin
Policy: Reshipping Policy
High Light:

81409 90 7 Oral Anabolic Steroids

,

Cabergoline Dostinex Oral Anabolic Steroids

,

81409 90 7 Oral Pills

Oral Anabolic Steroids Cabergoline Caber Dostinex CAS 81409-90-7

 

INDICATIONS


DOSTINEX Tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas.

 

DOSAGE AND ADMINISTRATION


The recommended dosage of DOSTINEX Tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient's serum prolactin level. Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease.

 

Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. Patients receiving long term treatment with DOSTINEX should undergo periodic assessment of their cardiac status and echocardiography should be considered.

 

After a normal serum prolactin level has been maintained for 6 months, DOSTINEX may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with DOSTINEX should be reinstituted. The durability of efficacy beyond 24 months of therapy with DOSTINEX has not been established.

 

HOW SUPPLIED


DOSTINEX Tablets are white, scored, capsule-shaped tablets containing 0.5 mg cabergoline. Each tablet is scored on one side and has the letter P and the letter U on either side of the breakline. The other side of the tablet is engraved with the number 700.

DOSTINEX is available as follows:

Bottles of 8 tablets NDC 0013-7001-12

 

Storage


Store at controlled room temperature 20°to 25°C (68°to 77°F) [see USP].
SIDE EFFECTS
The safety of DOSTINEX Tablets has been evaluated in more than 900 patients with hyperprolactinemic disorders. Most adverse events were mild or moderate in severity.

In a 4-week, double-blind, placebo-controlled study, treatment consisted of placebo or cabergoline at fixed doses of 0.125, 0.5, 0.75, or 1.0 mg twice weekly. Doses were halved during the first week. Since a possible dose-related effect was observed for nausea only, the four cabergoline treatment groups have been combined. The incidence of the most common adverse events during the placebo-controlled study is presented in the following table.
In the 8-week, double-blind period of the comparative trial with bromocriptine, DOSTINEX (at a dose of 0.5 mg twice weekly) was discontinued because of an adverse event in 4 of 221 patients (2%) while bromocriptine (at a dose of 2.5 mg two times a day) was discontinued in 14 of 231 patients (6%). The most common reasons for discontinuation from DOSTINEX were headache, nausea and vomiting (3, 2 and 2 patients respectively); the most common reasons for discontinuation from bromocriptine were nausea, vomiting, headache, and dizziness or vertigo (10, 3, 3, and 3 patients respectively). The incidence of the most common adverse events during the double-blind portion of the comparative trial with bromocriptine is presented in the following table.

 

General


Initial doses higher than 1.0 mg may produce orthostatic hypotension. Care should be exercised when administering DOSTINEX with other medications known to lower blood pressure.

Postpartum Lactation Inhibition or Suppression
DOSTINEX is not indicated for the inhibition or suppression of physiologic lactation. Use of bromocriptine, another dopamine agonist for this purpose, has been associated with cases of hypertension, stroke, and seizures.

Hepatic Impairment
Since cabergoline is extensively metabolized by the liver, caution should be used, and careful monitoring exercised, when administering DOSTINEX to patients with hepatic impairment.

Psychiatric
Pathological gambling, increased libido, and hypersexuality have been reported in patients treated with dopamine agonists including cabergoline. This has been generally reversible upon reduction of the dose or treatment discontinuation (See Postmarketing Surveillance data).

Carcinogenesis, Mutagenesis, Impairment Of Fertility
Carcinogenicity studies were conducted in mice and rats with cabergoline given by gavage at doses up to 0.98 mg/kg/day and 0.32 mg/kg/day, respectively. These doses are 7 times and 4 times the maximum recommended human dose calculated on a body surface area basis using total mg/m /week in rodents and mg/m /week for a 50 kg human.

There was a slight increase in the incidence of cervical and uterine leiomyomas and uterine leiomyosarcomas in mice. In rats, there was a slight increase in malignant tumors of the cervix and uterus and interstitial cell adenomas. The occurrence of tumors in female rodents may be related to the prolonged suppression of prolactin secretion because prolactin is needed in rodents for the maintenance of the corpus luteum. In the absence of prolactin, the estrogen/progesterone ratio is increased, thereby increasing the risk for uterine tumors. In male rodents, the decrease in serum prolactin levels was associated with an increase in serum luteinizing hormone, which is thought to be a compensatory effect to maintain testicular steroid synthesis. Since these hormonal mechanisms are thought to be species-specific, the relevance of these tumors to humans is not known.

 

The mutagenic potential of cabergoline was evaluated and found to be negative in a battery of in vitro tests. These tests included the bacterial mutation (Ames) test with Salmonella typhimurium, the gene mutation assay with Schizosaccharomyces pombe P1 and V79 Chinese hamster cells, DNA damage and repair in Saccharomyces cerevisiae D4, and chromosomal aberrations in human lymphocytes. Cabergoline was also negative in the bone marrow micronucleus test in the mouse.

 

In female rats, a daily dose of 0.003 mg/kg for 2 weeks prior to mating and throughout the mating period inhibited conception. This dose represents approximately 1/28 the maximum recommended human dose calculated on a body surface area basis using total mg/m /week in rats and mg/m /week for a 50 kg human.

 

Other Products List:

 

INJECTION LIQUID Specification
Dianabol 50 50mg/ml
Dianabol 80 80mg/ml
Anadrol 50 50mg/ml
Anavar 50 50mg/ml
Deca 200 200mg/ml
Deca 250 250mg/ml
NPP 200 200mg/ml
Nandrolone 200 (Nandrolone Cypionate) 200mg/ml
Boldenone 200 (Boldenone Cypionate) 200mg/ml
Boldenone 300 (Boldenone undecylenate) 300mg/ml
Cypoject 250 (Testosterone Cypionate) 250mg/ml
Enanject 250 (Testosterone Enanthate) 250mg/ml
Enanject 600 (Testosterone Enanthate) 600mg/ml
Propionat 100 (Testosterone Propionate) 100mg/ml
Propionat 200 (Testosterone Propionate) 200mg/ml
Sustanon 200 200mg/ml
Sustanon 250 250mg/ml
Sustanon 300 300mg/ml
Sustanon 400 400mg/ml
Undecanoate 500 (Testosterone Undecanoate) 500mg/ml
Trenabol 100 (Trenbolone Base) 100mg/ml
Trenabolic 80 (Trenbolone Acetate) 80mg/ml
Trenabolic 100 (Trenbolone Acetate) 100mg/ml
Trenabolic 200 (Trenbolone Acetate) 200mg/ml
Trenaject 60 (Trenbolone Enanthate) 60mg/ml
Trenaject 100 (Trenbolone Enanthate) 100mg/ml
Trenaject 150 (Trenbolone Enanthate) 150mg/ml
Trenaject 200 (Trenbolone Enanthate) 200mg/ml
Parabolone 50 (Trenbolone hexahydrobenzylcarbonate) 50mg/ml
Masteron 100 (Drostanolone Propionate) 100mg/ml
Masteron 200 (Drostanolone Enanthate) 200mg/ml
Primoject 100 (Methenolone Enanthate) 100mg/ml
TMT Blend 375 Trenbolone Enanthate 125mg/ml Drostanolone Enanthate 125mg/ml Testosterone Enanthate 125mg/ml
TM Blend 500 Trenbolone Enanthate 250mg/ml Drostanolone Enanthate 250mg/ml
   
ORAL LIQUID Specification
Name  
Dianabol 50 50mg/ml
Winstrol 25 (Stanozolol) 25mg/ml
Anadrol 50 50mg/ml
Anavar 20 20mg/ml
Clomid 50 (Clomiphene Citrate) 50mg/ml
Nolvadex 20 (Tamoxifen Citrate) 20mg/ml
Armidex 5 (Anastrozole) 5mg/ml
Femara 5 (Letrozole) 5mg/ml
Proviron 50 (Mesterolone) 50mg/ml

 

81409 90 7 Oral Anabolic Steroids Cabergoline Dostinex Pills 0

Contact Details
Hubei Yuancheng Saichuang Technology Co., Ltd.

Contact Person: Sales Manager

Tel: +8613429837396

Send your inquiry directly to us